Drug Trial Radar · NCT06625411
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
Last checked: Nov 20, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
132
Actual
Start
Aug 27, 2024
Primary completion
Feb 12, 2026
Study completion Nov 15, 2026
Sponsor
- Lead sponsor
- Viridian Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with active Thyroid Eye Disease (TED).
Conditions
- Thyroid Eye Disease
Interventions
VRDN-003Drug
VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).
PlaceboDrug
All participants will receive the same number of injections to maintain masking. Masking will be maintained by the use of placebo injections that appear identical to VRDN-003 injections.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proptosis Responder Rate in the most proptotic eye as measured by exophtalmometerTime frame: At Week 24
Locations
48 sites in 5 countries. Site status is shown where the registry gives one.
Scottsdale Clinical Trials
Scottsdale, Arizona
Alliance Research Institute - Canoga Park
Canoga Park, California
Marvel Clinical Research
Huntington Beach, California
United Medical Research Institute
Inglewood, California
Advancing Research International, LLC
Los Angeles, California
Roski Eye Institute, Keck School of Medicine, USC
Los Angeles, California
Alliance Research Institute - Lynwood
Lynwood, California
A.P.J. Office
Newport Beach, California
Byers Eye Institute at Stanford University
Palo Alto, California
Pasadena Clinical Trials
Pasadena, California
Cockerham Eye Consultants, PC
San Diego, California
C&A Clinical Trials Corp
Cape Coral, Florida
Ilumina Medical Research
Kissimmee, Florida
Med-Care Research
Miami, Florida
Continental Clinical Research
Miami, Florida
Hype Clinical Research LLC
Miami, Florida
Anmed Health Services LLC
Miami, Florida
Sarasota Retina Institute
Sarasota, Florida
Agile Clinical Research Trials, LLC
Atlanta, Georgia
Vision Medical Research
Orland Park, Illinois
Opthalmic Consultants of Boston
East Weymouth, Massachusetts
Fraser Eye Care Center
Fraser, Michigan
Kahana Oculoplastic & Orbital Surgery
Livonia, Michigan
University Health
Kansas City, Missouri
S.L. Office
Las Vegas, Nevada
Vector Clinical Trials
Sparks, Nevada
Rutgers New Jersey Medical School
Newark, New Jersey
Asheville Clinical Research
Asheville, North Carolina
Duke Eye Center
Durham, North Carolina
Baylor College of Medicine/Alkek Eye Center
Houston, Texas
Gulf Coast Clinical Trials
Houston, Texas
Neuro-Eye Clinical Trials
Houston, Texas
University of Washington, Eye institute
Seattle, Washington
West Virginia University Eye Institute
Morgantown, West Virginia
Charité Universitätsmedizin Berlin KöR
Berlin, Germany
Universitätsklinikum Carl- Gustav- Carus- Dresden
Dresden, Germany
Klinikapotheke des Universitätsklinikums Gießen und Marburg GmbH (UKGM)
Giessen, Germany
Universitaetsmedizin Goettingen
Göttingen, Germany
Budapest Retina Intezet
Budapest, Hungary
Pecsi Tudomanyegyetem Klinikai Kozpont, Szemeszeti Klinika
Pécs, Hungary
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.